Revolution Medicines, Inc. entered into four separate lease agreements for approximately 672,000 rentable square feet of office space in Redwood City, California, to serve as its new headquarters. The leases feature staggered commencement dates between September 2027 and September 2028, with initial terms ending in September 2042 and options for three additional five-year extensions. Aggregate scheduled monthly base rent begins at approximately $2.7 million, increasing by 3% annually, subject to a rent abatement of roughly $23.1 million through January 2030. The company will receive tenant improvement allowances totaling approximately $115.9 million, with an option for up to $40.3 million in additional allowances. The transaction is contingent on the landlords' acquisition of the properties by December 31, 2026, or April 29, 2027. Revolution Medicines operates in the biotechnology industry, focusing on the discovery and development of targeted therapies for cancer.

On August 26, 2026, the U.S. Food and Drug Administration approved RASONQUE (daraxonrasib) for adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. The approval was based on data from the global, randomized Phase 3 RASolute 302 clinical trial comparing RASONQUE to investigator’s choice of cytotoxic chemotherapy. Once-daily oral tablets are now available in the United States, with a wholesale acquisition cost of $39,800 for a 30-day supply based on the recommended daily dose. Revolution Medicines operates as a biopharmaceutical company focused on developing targeted therapies for cancer.

Revolution Medicines reported a net loss of $644.4 million for the quarter ended June 30, 2026, compared to $247.8 million in the prior year period. The increase was driven by higher R&D expenses of $394.9 million and G&A expenses of $110.2 million, partially offset by a non-cash warrant liability revaluation charge of $151.0 million. Cash reserves stood at $3.9 billion following a $2.225 billion equity and convertible note offering in April 2026 and a $250 million royalty tranche payment from Royalty Pharma in May 2026. The company updated its full-year 2026 GAAP operating expense guidance to $2.1–$2.2 billion. Clinically, the FDA accepted the New Drug Application for daraxonrasib for previously treated metastatic pancreatic cancer, and the company achieved U.S. commercial launch readiness while expanding an Expanded Access Program to over 2,000 patients. Revolution Medicines operates in the biotechnology industry, developing targeted therapies for RAS-addicted cancers.

Steve Kelsey, M.D., President of Research and Development, announced his intent to retire effective January 4, 2027. He will transition to senior advisor to the CEO on July 1, 2026, and the company intends to appoint him to the board of directors upon his retirement, subject to approval. The company also reported results from its June 18, 2026 annual meeting, where stockholders elected Alexis Borisy and Mark A. Goldsmith as Class III directors, ratified PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026, and approved executive compensation on an advisory basis. Revolution Medicines is a clinical-stage biopharmaceutical company that develops targeted therapies for cancer.